bi-2536

Small moleculeexperimental

Clinical trial activity

11 trials · 4 clinical orgs · 0 marketing orgs

Phase 1
5
Phase 2
6
Phase 3
0
Phase 4
0

Earliest trial started Aug 1, 2004 (NCT02211859)

Timeline

2000s

  1. Jan 1, 2004

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2006

    Earliest Phase 2 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

CC[C@@H]1C(=O)N(C)c2cnc(Nc3ccc(C(=O)NC4CCN(C)CC4)cc3OC)nc2N1C1CCCC1
Mol. weight
521.67 g/mol
Lipinski Ro5
1 violation(s)
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • bi2536
  • bi 2536
  • bi 2536
  • bi 2536
  • bi-2536
  • bi-2536
  • bi-2536

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT00526149Phase 2Jul 1, 2007European Organisation for Research and Treatment of Cancer, Katholieke Universiteit Leuven
NCT02215044Phase 1Jun 1, 2007Boehringer Ingelheim
NCT00412880Phase 2Jan 1, 2007Boehringer Ingelheim
NCT02211833Phase 1Oct 1, 2006Boehringer Ingelheim
NCT00701766Phase 2Oct 1, 2006Boehringer Ingelheim
NCT00706498Phase 2Sep 1, 2006Boehringer Ingelheim
NCT00710710Phase 2Aug 1, 2006Boehringer Ingelheim
NCT00376623Phase 2Jul 1, 2006Boehringer Ingelheim
NCT00243087Phase 1Jul 1, 2005Boehringer Ingelheim, University of Nebraska
NCT02211859Phase 1Aug 1, 2004Boehringer Ingelheim
NCT02211872Phase 1Aug 1, 2004Boehringer Ingelheim
Showing 11 of 11 trials
Page 1 / 1

Organizations

Research & Development (4)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Boehringer IngelheimFor profit101022004
European Organisation for Research and Treatment of CancerAcademic/Hospital1112007
Katholieke Universiteit LeuvenAcademic/Hospital1012007
University of NebraskaAcademic/Hospital1012005
4 organizations
Page 1 / 1